Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

Phase 1

Terminated

• Conditions: Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Advanced Solid Tumor; Refractory Tumor; Metastatic Tumor
• Interventions: Drug: AFM24; Biological: SNK01

• Registration Number: NCT05099549
• Lead Sponsor: NKGen Biotech, Inc.

Brief Summary

This is an open-label, multi-center study to evaluate the safety, tolerability, and anti-tumor activity of SNK01 in combination with AFM24 in subjects with advanced or metastatic EGFR-expressing cancers.

Detailed Description

The study will be conducted in two phases. The Phase 1/dose escalation phase will gather preliminary safety and tolerability data for escalating doses of AFM24 in combination with SNK01 at a fixed dose in order to determine the MTD/RP2D for the combination dose regimen to be used in the Phase 2a/expansion.

The Phase 2a/expansion portion of the study will gather additional safety, tolerability, efficacy, and anti-tumor activity information for the combination of AFM24 with SNK01 in subjects with three types of advanced or metastatic EGFR-expressing cancers.

Study Timeline

• Study First Submitted: 2021-10-18
• Study First Submitted QC: 2021-10-18
• Study First Posted: 2021-10-29
• Study Start: 2021-11-03
• Status Verified: 2023-07
• Primary Completion: 2023-09-21
• Study Completion: 2023-09-21
• Last Update Submitted: 2024-02-28
• Last Update Posted: 2024-03-01

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 11

Inclusion Criteria

1. Capable of giving signed informed consent

2. Males and females age ≥ 18 years

3. Phase 1/Dose Escalation : any histologically confirmed advanced or metastatic EGFR-positive malignancy for which all standard of care treatment options have been received and are no longer effective or are considered inappropriate at the discretion of the investigator.

4. Phase 2a/Expansion : histologically confirmed advanced or metastatic EGFR positive malignancy of mCRC (EXP-1 cohort), SCCHN (EXP-2 cohort) or NSCLC (EXP-3 cohort).

5. Additional Criteria for Phase 2a/Expansion: subjects must have a disease history specific to their disease as listed below:

   1. EXP-1: mCRC. Metastatic colorectal cancer (mCRC) MSI low/DNA mismatch repair proficient. Subjects must have received ≥ 1 lines of previous combination therapy and must have been exposed to oxaliplatin, irinotecan, a fluoropyrimidine, a VEGF targeting agent and, if considered appropriate by the treating physician, an EGFR targeted antibody.
   2. EXP-2: SCCHN. Subjects with advanced or metastatic SCCHN whose disease has progressed after having received ≥ 1 prior lines of therapy for advanced disease, which must have included platinum-based therapy, fluoropyrimidine, and an anti PD 1/PD-L1 antibody.
   3. EXP-3: NSCLC. Subjects with advanced or metastatic EGFR-expressing NSCLC (EGFR WT) whose disease has progressed after having received ≥ 1 prior lines of therapy for advanced disease. Subjects must have received at least a platinum-based doublet in combination with anti-PD1/PD-L1 antibody or must have received a platinum-based doublet followed by an anti-PD1/PD-L1 antibody.

6. One or more measurable tumors lesions per RECIST v1.1

7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

8. Adequate bone marrow, hepatic and renal function.

Key

Exclusion Criteria

1. Superior vena cava syndrome contra-indicating hydration
2. Untreated or symptomatic central nervous system (CNS) metastases
3. No resolution of specific toxicities related to any prior anti-cancer therapy to Grade ≤ 1 according to the NCI-CTCAE v.5.0 (except peripheral or motor neuropathy, lymphopenia and alopecia)
4. Treatment with systemic anticancer therapy or an investigational device within 4 weeks (6 weeks if therapy was mitomycin C and/or nitrosoureas), or within 5 half-lives of the agent (if half-life is known and it is shorter) before the first dose of study treatment.
5. Radiation therapy within 2 weeks before first dose of any study treatment or unresolved (NCI CTCAE v5.0 Grade > 1) toxicity from previous radiotherapy
6. Clinically significant cardiovascular disease
7. Major surgery within 4 weeks prior to any study treatment administration
8. Any pulmonary, thyroid, renal, hepatic severe/uncontrolled concurrent medical disease that in the opinion of the Investigator could cause unacceptable safety risks or compromise compliance with the protocol
9. Active uncontrolled viral, fungal, or bacterial infection requiring systematic therapy within 14 days prior to first dose of study treatment.
10. Known history of testing positive for human immunodeficiency virus (HIV), and/or positive test for Hepatitis B virus surface antigen (HBsAg) and/or positive Hep C antibody result with detectable hepatitis C virus (HCV) ribonucleic acid (RNA) indicating acute or chronic infection.
11. Autoimmune disease requiring therapy; immunodeficiency, or any disease process requiring systemic immunosuppressive therapy
12. A serious nonmalignant disease that could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor
13. Any other condition that, in the opinion of the Investigator, would prohibit the subject from participating in the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Phase 1, Dose Escalation	AFM24	It is estimated that approximately 3-6 subjects will be enrolled per cohort in three dose cohorts for a total of 12-18 participants. SNK01 (fixed dose) will be administered weekly by IV infusion.
Phase 1, Dose Escalation	SNK01	It is estimated that approximately 3-6 subjects will be enrolled per cohort in three dose cohorts for a total of 12-18 participants. SNK01 (fixed dose) will be administered weekly by IV infusion.
Phase 2a, Expansion Cohort 1 - Metastatic colorectal cancer (EXP-1: mCRC)	AFM24	SNK01 (fixed dose) will be administered weekly by IV infusion.
Phase 2a, Expansion Cohort 1 - Metastatic colorectal cancer (EXP-1: mCRC)	SNK01	SNK01 (fixed dose) will be administered weekly by IV infusion.
Phase 2a, Expansion Cohort 2 - Head and Neck Squamous Cell Carcinoma (EXP-2: SCCHN)	AFM24	SNK01 (fixed dose) will be administered weekly by IV infusion.
Phase 2a, Expansion Cohort 2 - Head and Neck Squamous Cell Carcinoma (EXP-2: SCCHN)	SNK01	SNK01 (fixed dose) will be administered weekly by IV infusion.
Phase 2a, Expansion Cohort 3 - Non-small cell lung cancer (EXP-3: NSCLC)	AFM24	SNK01 (fixed dose) will be administered weekly by IV infusion.
Phase 2a, Expansion Cohort 3 - Non-small cell lung cancer (EXP-3: NSCLC)	SNK01	SNK01 (fixed dose) will be administered weekly by IV infusion.

Primary Outcome Measures

Name	Time	Method
Phase 1/Dose Escalation	28 days starting on cycle 1 day 1	Determine the recommended phase 2 dose (RP2D) of AFM24 in combination with SNK01.; To be assessed by the incidence and severity of dose-limiting toxicity (DLT) within the DLT observation period.
Phase 2a/Expansion	Up to 24 months	Determine objective response rate (ORR) of AFM24 in combination with SNK01. Determine ORR using Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1

Secondary Outcome Measures

Name	Time	Method
Phase 1/Dose Escalation	Up to 24 months	Immunogenicity of AFM24 when AFM24 is given in combination with SNK01 Frequency of subjects developing AFM24 anti drug antibodies (ADAs) through completion of the Phase 1/dose escalation portion
Phase 2a/Expansion	Up to 24 months	Immunogenicity of AFM24 when AFM24 is given in combination with SNK01 Frequency of subjects developing AFM24 ADAs and frequency of subjects developing neutralizing ADAs.

Trial Locations

Locations (3)

USC/Norris Comprehensive Cancer Center; 🇺🇸 Los Angeles, California, United States

Sarcoma Oncology Center; 🇺🇸 Santa Monica, California, United States

University of Chicago; 🇺🇸 Chicago, Illinois, United States